Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Biophytis

BRIEF

published on 11/13/2025 at 18:35, 21 days 11 hours ago

Results of Biophytis' General Meeting Held on November 13, 2025

Financial Statements Biophytis Shareholder Approval General Meeting Thérapies
REGULATED PRESS RELEASE

published on 11/13/2025 at 18:30, 21 days 11 hours ago

RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
Biophytis SA announces the approval of all resolutions at the combined general meeting held on November 13, 2025, impacting longevity therapies development. Shareholder mobilization led to a 31% quorum

Longevity Therapies Combined General Meeting Biophytis SA Shareholder Mobilization Approval Of Resolutions
BRIEF

published on 10/30/2025 at 23:05, 1 month 5 days ago

Biophytis Announces Strategic Partnerships and Financial Results for H1 2025

Financial Results Strategic Partnerships Obesity Treatment Sarcopenia Clinical Trial Biophytis Expansion
REGULATED PRESS RELEASE

published on 10/30/2025 at 23:00, 1 month 5 days ago

Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports first-half 2025 financial results and strategic update, including milestones in sarcopenia and obesity, highlighting expansion plans and financial elements

Financial Results Biophytis Sarcopenia Strategic Update Obesity
PRESS RELEASE

published on 10/30/2025 at 22:59, 1 month 5 days ago

Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports financial results for the first half of 2025, strategic update, and key achievements in sarcopenia and obesity. Plans for Phase 2 and Phase 3 studies outlined with focus on sustaining growth and value creation

Financial Results Biophytis Sarcopenia Strategic Update Obesity
BRIEF

published on 10/13/2025 at 07:05, 1 month 22 days ago

Biophytis and Asian Investors to Launch Phase 3 Sarcopenia Trial

Biophytis Phase 3 Trial Sarcopenia BIO101 Asian Investors
REGULATED PRESS RELEASE

published on 10/13/2025 at 07:00, 1 month 22 days ago

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
BIOPHYTIS and a Consortium of Investors partner to finance and launch Phase 3 Trial in Sarcopenia, creating a joint venture in Hong Kong with US$20 million investment for clinical operations starting early 2026

Biophytis Joint Venture Phase 3 Trial Sarcopenia Consortium Of Investors
BRIEF

published on 09/30/2025 at 07:05, 2 months 4 days ago

Biophytis to Engage in Key Events in Q4 2025

Biophytis Partnerships Longevity Sarcopenia Biotechnology Events
REGULATED PRESS RELEASE

published on 09/30/2025 at 07:00, 2 months 4 days ago

Biophytis to Participate in Four Key Events in Q4 2025
Biophytis to participate in four major international events in Q4 2025, showcasing its progress in transformative therapies impacting longevity and seeking new partnerships

Biophytis Partnerships Longevity International Events Transformative Therapies
BRIEF

published on 09/15/2025 at 07:05, 2 months 19 days ago

Biophytis Secures Funding for Obesity Trial in Brazil

Biophytis Brazil Obesity Trial EMBRAPII Clinical Partnerships

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 37 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 13 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 27 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE